Matthew Benz, MD
Ophthalmology · Houston, TXNPI 1689771545
Payments from drug & device makers
Across 58 payments — averaging $144.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Regeneron$3K
- Apellis Pharmaceuticals, Inc.$370
- Genentech USA, Inc.$362
- Regeneron Healthcare Solutions, Inc.$255
- Astellas Pharma US Inc$187
- plus $372 from 6 others
What the payments were for
- Consulting fees$6,60079%
- Travel & lodging$651%
- Food & beverage$1,70120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $3,820 |
| Regeneron | 1 | $3,000 |
| Apellis Pharmaceuticals, Inc. | 13 | $370 |
| Genentech USA, Inc. | 13 | $362 |
| Regeneron Healthcare Solutions, Inc. | 6 | $255 |
| Astellas Pharma US Inc | 3 | $187 |
| Coherus Oncology, Inc. | 3 | $125 |
| Biogen | 5 | $105 |
| Eyepoint US, Inc. | 1 | $68 |
| Novartis | 2 | $38 |
| Neurotech Pharmaceuticals, Inc. | 1 | $18 |
| Alimera Sciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,366 in reported general payments places this provider in the 80th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 29 | $11,447 |
| Prednisolone Acetate | 100 | $4,633 |
| Latanoprost | 107 | $1,256 |
| MoxifloxacinMoxifloxacin Hcl | 49 | $1,062 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $935 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 60 | $850 |
| Atropine Sulfate | 20 | $793 |
| Ketorolac Tromethamine | 24 | $343 |
| Timolol Maleate | 16 | $306 |
| Brimonidine Tartrate | 28 | $189 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- David BrownHouston$51.7M
- John MichelettiHouston$3.3M
- Michael CaplanHouston$1.4M
- Shaheen KavoussiHouston$1.3M
- Kevin JongHouston$1.2M
- Stephen SladeHouston$1.2M
- Rosa TangHouston$1.1M
- Zaina Al-MohtasebHouston$1.1M
- Fiaz ZamanHouston$1M
- Stephen PflugfelderHouston$788K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.